Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Getting Personal: Better Diagnosis, Better Treatment
Posted on September 8th, 2017 by Betsy Davis in Pharma R&D
Figures released by the U.S. National Cancer Institute (NCI) in 2017 indicate that the burden of cancer is on the rise, with the number of diagnoses rising by 50% over the next 13 years. Even more troubling is the predicted mortality rate for cancer, Continue reading “Getting Personal: Better Diagnosis, Better Treatment” »
FDA Speeds Up Generic Approval Process
Posted on August 30th, 2017 by Xuanyan Xu in Pharmacovigilance
Healthcare has been in the spotlight for much of the year so far, as Congress has wrestled with the difficult question of how to make it both better and more affordable.
Assessing DDI Risk in the Digital Age
Posted on August 9th, 2017 by Sherry Winter in Pharmacovigilance
In their 2012 Drug Regulations, the U.S. Food and Drug Administration recommended that “pharmacokinetic interactions between an investigational new drug and other drugs should be defined during drug development.”
The Link Between Big Pharma and the Supplement Industry
Posted on July 28th, 2017 by Betsy Davis in Pharma R&D
When the FDA updated some of its guidelines around dietary supplements last year, many critics of the supplement (or “nutraceutical”) business were pleased to see a bit more regulation in an industry that enjoys surprisingly little oversight. Continue reading “The Link Between Big Pharma and the Supplement Industry” »
